Discovering New Drugs in One Step
DeepCovalent’s One-Step-Denovo Drug Discovery (OS3D™) is a multimodal, multi-objective generative AI engine that designs clinically viable, synthesis-ready de novo small molecules in a single forward pass. Purpose-built to address the central bottlenecks in early discovery — slow, capital-intensive R&D workflows and the > 90% clinical failure rate driven by incomplete biological and ADMET understanding — OS3D™ enables rapid, constraint-aware drug molecule generation with significantly higer downstream success.
Ideation to Validated Molecules in 3 Weeks
OS3D™ compresses early-stage discovery from months to ≤ 3 weeks, enabling low-cost, de-risked evaluation of new or deprioritized targets and creating early pipeline optionality.
Scientific Validation
OS3D™ has been in-silico validated on FDA-approved drugs and across DeepCovalent’s internal discovery programs. Contact us to request the white paper and learn more.
Pipelines
DeepCovalent is developing viable therapeutic pipelines powered by OS3D™. Learn more about our pipelines here.